New York Medicaid and semaglutide
Wegovy for weight loss: no. Drug list row: cardiovascular disease with BMI of 40 or higher, lifestyle changes, two treatment attempts per lifetime. Ozempic for weight loss: no; for type 2 diabetes New York Medicaid must cover it. Read from New York State Department of Health documents Nov 6, 2026.
In 2025 New York Medicaid paid for 488,820 semaglutide prescriptions (Ozempic, Rybelsus, Wegovy), 60% of its GLP-1 prescriptions and 2nd of the 50 states and DC. It reimbursed $573.9 million before rebates, $1,174 a prescription against $1,104 nationally.
| Brand | Prescriptions | Medicaid paid | Per Rx |
|---|---|---|---|
| Ozempic | 464,371 | $541.1 million | $1,165 |
| Rybelsus | 24,252 | $32.6 million | $1,345 |
| Wegovy | 197 | $214,617 | $1,089 |
New York plans and prescribing rules
Empire Plan (NYSHIP). The Empire Plan's January 2026 Advanced Flexible Formulary lists Wegovy and Zepbound as preferred anti-obesity agents, each requiring prior authorization.
Semaglutide in the states around New York
| State | Sell semaglutide, ship there | Cheapest | Medicaid Rx, 2025 | Medicaid, Wegovy for weight loss |
|---|---|---|---|---|
| New York | 19 | $39/moWellmedr | 488,820 | Medicaid Wegovy: No |
| Connecticut | 19 | $39/moWellmedr | 107,061 | Medicaid Wegovy: No |
| Massachusetts | 18 | $39/moWellmedr | 53,347 | Medicaid Wegovy: No |
| New Jersey | 19 | $39/moWellmedr | 71,402 | Medicaid Wegovy: Not covered (KFF) |
| Pennsylvania | 19 | $39/moWellmedr | 485,068 | Medicaid Wegovy: No |
| Vermont | 19 | $39/moWellmedr | 8,393 | Medicaid Wegovy: No |



